Barbara Pro

Grants

Grants per year

2006 2023

• 6 Finished
• 7 Active

Grants per year

Search results

• Active

  Prot #NU MSK19H03: A Phase II Study of Pembrolizumab and Entinostat in Patients with Relapsed and Refractory Lymphomas (17-073)

  Pro, B.

  Memorial Sloan-Kettering Cancer Center

  9/17/20 → 9/17/23

  Project: Research project

• Prot #ASTX660-01: Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas

  Pro, B.

  Astex Pharmaceuticals, Inc.

  10/17/18 → 10/17/21

  Project: Research project

• Prot #VS-0145-225: A Muti-Center, Phase 2, Open Label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

  Pro, B.

  Parexel, Verastem, Inc.

  8/6/18 → 8/6/21

  Project: Research project

• Prot #X16042: A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib as Frontline Therapy for Patients with MYC-aberrant Lymphoid Malignancies: The DACIPHOR Regimen

  Pro, B.

  Millennium Pharmaceuticals, Inc

  6/1/15 → 6/1/21

  Project: Research project

• Prot #RV-CL-PTCL-PI-003974: NU 14H04: Phase II Study of Romidepsin Plus Lenalidomide for Patients with Previously Untreated PTCL

  Pro, B.

  Celgene Corporation

  5/14/15 → 5/14/21

  Project: Research project

• Prot #PCI-32765MCL2003: NU 14H06: A Phase II Clinical Trial Evaluating Ibrutinib Maintenance Following Intensive Induction for Patients with Previously Untreated Mantle Cell Lymphoma (MCL)

  Kaplan, J. B. & Pro, B.

  Janssen Scientific Affairs, LLC

  1/6/15 → 1/6/23

  Project: Research project

• Prot #C25003: A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

  Pro, B.

  ICON Clinical Research, LLC, Millennium Pharmaceuticals, Inc

  10/2/13 → 10/31/20

  Project: Research project

• Finished

  Prot #APL-B-021-13: A Phase II Study of Plitidepsin in Patients with Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma

  Pro, B.

  Pharma Mar, S.A. Sociedad Unipersonal

  2/28/17 → 2/28/20

  Project: Research project

• Prot #D4190C00023: A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination with Tremelimumab or AZD9150 in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma

  Pro, B.

  ICON Clinical Research, LLC, MedImmune, LLC

  4/29/16 → 4/29/19

  Project: Research project

• Prot #BO29337: A Phase II, Open-Label Study Evaluating the Safety and Efficacy of GDC-0199 (ABT-199) Plus Bendamustine Plus Rituximab (BR) in Comparison with BR Alone or GDC-0199 Plus Rituximab (R) in Patients with Relapsed and Refractory Follicular Non-H

  Pro, B.

  Covance Inc., Genentech, Inc.

  4/10/15 → 4/30/20

  Project: Research project

• Prot #0761-010: Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma

  Kuzel, T. M. & Pro, B.

  Kyowa Hakko Kirin Pharma, Inc.

  2/12/13 → 2/12/19

  Project: Research project

• Prot# C25001: A Randomized, Open-Label, Phase 3 Trial of brentuximab vedotin (SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

  Kuzel, T. M. & Pro, B.

  ICON Clinical Research, LLC, Millennium Pharmaceuticals, Inc

  6/15/12 → 6/15/18

  Project: Research project

• Prot# H3E-US-X065 / NU 05H8: Phase I/II Trial of Gemcitabine/Pemetrexed Combination in Patients with Advanced Cutaneous T-Cell Lymphoma

  Guitart, J., Kuzel, T. M. & Pro, B.

  Eli Lilly and Company

  6/7/06 → 9/30/13

  Project: Research project